Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03), Zacks reports.
Fulcrum Therapeutics Price Performance
Fulcrum Therapeutics stock traded up $0.22 during mid-day trading on Friday, hitting $3.59. The company's stock had a trading volume of 368,499 shares, compared to its average volume of 463,136. Fulcrum Therapeutics has a 52-week low of $2.86 and a 52-week high of $13.70. The company has a market cap of $193.64 million, a PE ratio of -11.58 and a beta of 2.03. The firm's 50 day moving average is $4.12 and its 200 day moving average is $4.61.
Wall Street Analyst Weigh In
FULC has been the topic of several recent analyst reports. Royal Bank of Canada reiterated a "sector perform" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright reiterated a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of "Hold" and an average price target of $9.33.
Read Our Latest Research Report on FULC
About Fulcrum Therapeutics
(
Get Free Report)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
See Also
Before you consider Fulcrum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.
While Fulcrum Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
